CervoMed (CRVO) Total Liabilities (2010 - 2026)
CervoMed (CRVO) posted Total Liabilities of $4.5 million for Q1 2026, down 3.41% sequentially from $4.7 million in Q4 2025, and up 14.06% YoY from $3.9 million in Q1 2025.
CervoMed (CRVO) Total Liabilities (2010 - 2026) Analysis & Trends
CervoMed has reported Total Liabilities for 17 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Total Liabilities rose 14.06% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 14.06% YoY) and the FY2025 annual result came in at $4.7 million, up 20.03% from the prior year.
- Total Liabilities fell to $4.5 million in Q1 2026 per CRVO's latest filing, from $4.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $33.6 million in Q1 2022 and troughed at $2.1 million in Q1 2023.
- A 5-year average of $9.3 million and a median of $4.5 million in 2026 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 1208.52% in 2022, then plunged 93.67% in 2023.
- Over 5 years, Total Liabilities stood at $13.2 million in 2022, then slumped by 80.27% to $2.6 million in 2023, then soared by 49.45% to $3.9 million in 2024, then advanced by 20.03% to $4.7 million in 2025, then fell by 3.41% to $4.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $4.5 million, $4.7 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | CervoMed | 26.12 Mn | 26.12 Mn | - | 3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.03 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 4.66 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.64 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 2.60 Mn |
| Sep 30, 2023 | 2.46 Mn |
| Jun 30, 2023 | 14.19 Mn |
| Mar 31, 2023 | 2.13 Mn |
| Dec 31, 2022 | 13.16 Mn |
| Sep 30, 2022 | 26.32 Mn |
| Jun 30, 2022 | 29.18 Mn |
| Mar 31, 2022 | 33.57 Mn |
| Dec 31, 2021 | 2.93 Mn |
| Sep 30, 2021 | 2.75 Mn |